DK1011678T3 - Use of mecamylamine for the treatment of nicotine-responsive neuropsychiatric disorders - Google Patents

Use of mecamylamine for the treatment of nicotine-responsive neuropsychiatric disorders

Info

Publication number
DK1011678T3
DK1011678T3 DK98939328T DK98939328T DK1011678T3 DK 1011678 T3 DK1011678 T3 DK 1011678T3 DK 98939328 T DK98939328 T DK 98939328T DK 98939328 T DK98939328 T DK 98939328T DK 1011678 T3 DK1011678 T3 DK 1011678T3
Authority
DK
Denmark
Prior art keywords
mecamylamine
nicotine
treatment
neuropsychiatric disorders
responsive
Prior art date
Application number
DK98939328T
Other languages
Danish (da)
Inventor
Paul Ronald Sanberg
Roland Douglas Shytle
Archie Aaron Silver
Original Assignee
Univ South Florida
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US1997/020689 external-priority patent/WO1999007356A1/en
Application filed by Univ South Florida filed Critical Univ South Florida
Application granted granted Critical
Publication of DK1011678T3 publication Critical patent/DK1011678T3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
DK98939328T 1997-08-11 1998-08-11 Use of mecamylamine for the treatment of nicotine-responsive neuropsychiatric disorders DK1011678T3 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US5523497P 1997-08-11 1997-08-11
US93536497A 1997-09-22 1997-09-22
PCT/US1997/020689 WO1999007356A1 (en) 1997-08-11 1997-11-07 Nicotine antagonists for neuropsychiatric disorders
PCT/US1998/016634 WO1999007378A1 (en) 1997-08-11 1998-08-11 Nicotine antagonists for nicotine-responsive neuropsychiatric disorders

Publications (1)

Publication Number Publication Date
DK1011678T3 true DK1011678T3 (en) 2008-05-05

Family

ID=27368798

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98939328T DK1011678T3 (en) 1997-08-11 1998-08-11 Use of mecamylamine for the treatment of nicotine-responsive neuropsychiatric disorders

Country Status (6)

Country Link
JP (1) JP4640888B2 (en)
AU (1) AU8778498A (en)
CA (1) CA2300148C (en)
DK (1) DK1011678T3 (en)
ES (1) ES2299214T3 (en)
WO (1) WO1999007378A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ID28441A (en) * 1998-10-16 2001-05-24 Janssen Pharmaceutica Nv THERAPY TO IMPROVE CONSCIOUSNESS
GB0102841D0 (en) * 2001-02-05 2001-03-21 Novartis Ag Organic compounds
JP2007516275A (en) * 2003-12-23 2007-06-21 ファイザー・プロダクツ・インク Therapeutic combinations for cognitive enhancement and psychotic disorders
US20060211686A1 (en) * 2005-03-18 2006-09-21 Abbott Laboratories Alpha7 Neuronal nicotinic receptor ligand and antipsychotic compositions
US11766429B1 (en) 2020-08-26 2023-09-26 University Of South Florida Nicotinic receptor antagonists and pioglitazone as therapeutic agents for Covid-19

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5691365A (en) * 1995-07-18 1997-11-25 University Of Kentucky Research Foundation Nicotinic receptor antagonists in the treatment of neuropharmacological disorders

Also Published As

Publication number Publication date
AU8778498A (en) 1999-03-01
JP2003524573A (en) 2003-08-19
WO1999007378A1 (en) 1999-02-18
CA2300148C (en) 2009-06-23
CA2300148A1 (en) 1999-02-18
JP4640888B2 (en) 2011-03-02
ES2299214T3 (en) 2008-05-16

Similar Documents

Publication Publication Date Title
DK1063990T3 (en) Use of Biochanine-Enriched Extract for the Treatment of Estrogen-Associated Disorders
DK1047428T3 (en) Use of morpholinol in the treatment of sexual disorders
IS5113A (en) Use of CB1 antagonists for the treatment of craving disorders
DK0830864T3 (en) Combination therapy for the treatment of psychoses
DK0916675T3 (en) Process for the preparation of sildenafil
DK0941103T3 (en) Pharmaceutical preparation for the treatment of diabetes
DK1028954T3 (en) Substituted imidazoles suitable for the treatment of inflammatory diseases
DK0861081T3 (en) Use of epinastine for the treatment of pain
DK1021194T3 (en) New improved formulation for the treatment of osteoporosis
DK0937055T3 (en) Process for the preparation of d, I-alpha-tocopherol
DK0752870T3 (en) Use of Mycobacterium for the treatment of tumors
DK199800837A (en) Installations for the treatment of subjects
DK1053217T3 (en) Process for the preparation of n-propanol
DK1027315T3 (en) Process for the preparation of n-butanol
DE59707096D1 (en) Hair treatment agent for setting the hair
DK1028960T3 (en) Process for the preparation of thiazolidinedione
IT1303677B1 (en) DEVICE FOR THE HEAT TREATMENT OF PIECES.
DK0928183T3 (en) Use of 1-hydroxy-2-pyridones for the treatment of seborrhoic dermatitis
DK0946514T3 (en) Process for the preparation of n-substituted 3-hydroxypyrazoles
DK1011678T3 (en) Use of mecamylamine for the treatment of nicotine-responsive neuropsychiatric disorders
DK0819113T3 (en) Benzamides for the treatment of neurodegenerative disorders
DK1200447T3 (en) Oxazinocarbazoles for the treatment of CNS diseases
DK0981349T3 (en) 5-alpha-pregnan-3-beta-ol-20-one sulfate for the treatment of tumors and CNS diseases
DK1012152T3 (en) Process for the preparation of oxazaphosphorin-2-amines
IS5481A (en) Combination therapy for the treatment of AIDS